Lactacystin (1), a structurally novel microbial product, was isolated from a Streptomyces strain and characterized by O ළ mura et al. 1, 2) from a screening program to detect nerve growth factor (NGF)-like activity (induction of neurite outgrowth) in a mouse neuroblastoma cell line (Neuro 2A). The structure was unequivocally determined as 1 by X-ray crystallographic studies.
Lactacystin (1), a structurally novel microbial product, was isolated from a Streptomyces strain and characterized by O ළ mura et al. 1, 2) from a screening program to detect nerve growth factor (NGF)-like activity (induction of neurite outgrowth) in a mouse neuroblastoma cell line (Neuro 2A). The structure was unequivocally determined as 1 by X-ray crystallographic studies.
2) A detailed investigation of the mode of biological action of lactacystin revealed that it did not function as a mimic of nerve growth factor. 3, 4) Instead, lactacystin has been found to act with exquisite specificity and in a unique fashion to inhibit irreversibly the proteolytic activity of the 20 S proteasome, a cylindrical complex of 28 protein subunits which is responsible for the hydrolytic fragmentation of ubiquitinated proteins. The thiol ester function of lactacystin is sufficiently reactive to allow spontaneous conversion to the b-lactone 2 5) which similarly deactivates the 20 S proteasome, but at a much faster rate. 4, 5) The major source of inactivation of the 20 S proteasome appears to be the acylation of the N-terminal threonine subunit, a key participant in proteolytic catalysis, 3, 4) to form inactivated proteasome as shown in Fig. 1 . This result was confirmed by X-ray crystallographic studies of the lactacystin-inactivated 20 S proteasome at 2.4 Å resolution. 6, 7) Because the proteasome machinery is involved in the degradation of many proteins, including not only misfolded and denatured molecules 8) but also proteins involved in cell cycle progression 9) and regulation of gene transcription, 10) lactacystin has emerged as a very important new tool for the study of protein biochemistry and cell biology. 11, 12) The key evidence which defined the mechanism of action of lactacystin may be summarized as follows. (1) Incubation of Neuro-2A cells with C(9) tritiated lactacystin (from chemical synthesis 3) ) labels with extraordinary selectivity a protein which was identified as a proteasome b-subunit by acetylation of the N-terminal threonine.
3) (2) The inactivation of the proteasome occurs in a time-dependent and irreversible manner by either lactacystin (1) or lactacystin b-lactone (2), 5) with the latter being much more reactive. (3) Lactacystin derivatives which can not form a b-lactone are inactive. 4) (4) A variety of ester analogs of lactacystin which are sufficiently reactive to form spontaneously the b-lactone 2, e.g. thiol esters or the 2,2,2-trifluoroethyl ester, are active. 4) (5) Lactacystin b-lactone (2) is formed from lactacystin in extracellular fluid and diffuses more readily through the cell membrane. 13) Because of the biological importance of 2 and the desirability of giving it a sample name, we have chosen to call it "omuralide" in this review. Lactacystin (1) and omuralide (2) are remarkable because they exemplify dramatically the ability of small molecules to shut down the functioning of a very large poly-macromolecular machine and to exert this inhibition with great selectivity on 20 S proteasome in the presence of countless other proteins as potential targets. The biological uniqueness and utility of lactacystin and omuralide and their structural novelty have made these molecules and their analogs attractive targets for chemical synthesis. This report reviews the studies carried out thus far in this field. It also summarized the current state of knowledge regarding the relationship of biological activity to chemical structure.
Initial Studies on the Total Synthesis of Lactacystin
The first total synthesis of lactacystin 14) and omuralide and refinements subsequently made to it 15) are summarized in Chart 1. The protected aminal 4, which was obtained from (S)-serine (3) in three standard steps, was converted diastereoselectively to the crystalline product 5 via the corresponding lithium enolate by reaction with isobutyraldehyde. The presence of added lithium bromide was required for diastereoselectivity. Acidic methanolysis of the aminal subunit in 5, silylation of the resulting primary alcohol function, formation of an oxazoline ring by methylene connection of secondary hydroxyl and amino functions, reduction of methoxycarbonyl group by LiBH 4 and modified Swern oxidation generated aldehyde 6. In the Swern oxidation step, it was advantageous to use a new modification in which the cold preformed Swern reagent (from Me 2 SO and oxalyl chloride at Ϫ78°C in CH 2 Cl 2 ) was added to a mixture of primary alcohol and Et 3 N in CH 2 Cl 2 solution at Ϫ78°C. The conventional Swern oxidation procedure leads to inefficient formation of aldehyde 6 along with several by-products.
The transformation of aldehyde 6 to the anti aldol product 8 was one of the most challenging step in the synthesis. Initial approaches using Heathcock's methodology 14) (lithium enolate of 2,6-dimethylphenyl propionate) or Braun's approach 16, 17) provided only moderate yields of the desired anti aldol product, and were unsatisfactory for use on larger scale. 15) As outlined in Chart 1, the Mukaiyama aldol coupling of 6 and 7 with MgI 2 as catalyst proceeded stereoselectively and in good yield, with no scale-up problems, to afford the aldol product 8. It is noteworthy that MgI 2 was uniquely effective as catalyst. 15) For example, use of SnCl 4 , ZnCl 2 or Cu(OTf ) 2 in CH 2 Cl 2 for the Mukaiyama aldol coupling of 6 and 7 produced none of the desired product 8.
15) The unique effectiveness of MgI 2 as catalyst in the reaction 6ϩ7 → 8 may be due to the ability of the small IMg ϩ species to form a chelate with the sterically congested amino aldehyde 6 as shown in Chart 2. 15) Because of steric screening at the re face of the formyl group this chelate undergoes nucleophilic attack at the si face. Preferential formation of the anti aldol product (anti/syn ratio ca. 10 : 1), appears also to be due to steric effects which favor the synclinal transition state over the antiperiplannar alternative as shown in Chart 2.
15)
The key aldol intermediate 8 was transformed into the dihydroxy lactam 9 by the sequence: (1) N-benzyl cleavage, (2) amino ester → g-lactam ring closure and (3) desilylation, as shown in Chart 1. Oxidation of the primary alcohol function of 9 produced the dihydroxy acid 10 which underwent selective b-lactonization to omuralide (2) when treated with bis(2-oxo-3-oxazolidenyl)phosphinic chloride (BOPCl) and Et 3 N. Finally, reaction of omuralide (2) with N-acetyl-(S )-cysteine produced lactacystin (1) quantitatively. The process has been used successfully to produce multigram amounts of these compounds. At present it appears to be the most effective synthesis of 1 and 2 in quantity. Very little chromatography is involved in this synthesis. In addition, the conversions 5 → 6, 8 → 9 and 9 → 10 can be carried out without purification of intermediates.
15) The initial aldol product 5 has been made on 100 g scale using only ordinary laboratory glassware and the conversion to lactacystin and omuralide can be accomplished in 40% overall yield.
The intermediates provided by the synthetic approach summarized in Chart 1 were also useful in providing analogs of lactacystin which are incapable of leading to b-lactone analogs of 2. These structures were obviously useful as tests of the hypothesis that the formation of omuralide might be a prerequisite for lactacystin function. As shown in Chart 3, the syn aldol diastereomer 11 of the anti aldol intermediate 8 could be converted via the lactam 12 to the (6R,7S)-diastereomer (13) of lactacystin by a sequence of reactions paralleling those used for the synthesis of lactacystin from 8 (Chart 1).
18) Intermediate 12 also served admirably for the synthesis of the 6-deoxy analog (14) of lactacystin. Both analogs 13 and 14 of lactacystin were found to be biologically inactive which underscored the possibility that the omuralide might Lactacystin has also been synthesized by Baldwin and coworkers starting with the (R)-glutamic acid-derived intermediate 23 which has the g-lactam ring of lactacystin already in place, along with an extra stereocenter for stereochemical control (Chart 5). 22, 23) a-Methylation of 23 and introduction of a,b-unsaturation provided 24 which was silylated to the interesting chiral pyrrole 25. Mukaiyama aldol reaction of 25 with isobutyraldehyde produced the required coupling product 26 in modest yield. Installation of the b-hydroxy lactam subunit required a number of steps which led to the hydroxy lactam 27, and finally to 1, as shown in Chart 5. 22, 23) Quite a different synthesis of 1 was developed by Chida et al. using D-glucose as starting material. 24, 25) This synthesis, though long, has several interesting features, as shown in Chart 6. Only four of the six carbons and one of the five stereocenters of D-glucose survive in the final product. C(4) of D-Glucose becomes C(7) of lactacystin. The C(5) quaternary stereocenter of 1 is created with 4 : 1 diastereoselectivity by Overman [3, 3] sigmatropic rearrangement (28 → 29). The generation of the C(9) stereocenter (30 → 31) suffered from lack of stereocontrol and low yield due to concomitant formyl reduction by isopropylmagnesium bromide. 24, 25) The first enantioselective synthesis of lactacystin from achiral compounds, dimethyl malonate derivative 28 and methyl N-p-methoxybenzylglycinate, is summarized in Chart 7.
26) Enantioselective pig liver esterase (PLE)-catalyzed hydrolysis followed by one recrystallization of the resulting monoacid as the quinine salt afforded the chiral acid 29 (S configuration, 95% ee) which was coupled to the glycine ester component and cyclized to give the chiral keto lactam 30. Hydroxymethylation of 30 and reduction of the ketonic carbonyl by internal hydroxyl-directed hydride delivery each occurred with high diastereoselectivity to form 31 (99% ee after one recrystallization), the structure of which was confirmed by X-ray crystallographic analysis. 26) After conversion of 31 to the aldehyde 32, reaction of 32 with the 2-propenyl Grignard reagent in the presence of trimethylchlorosilane (essential to avoid retroaldol cleavage) provided the required adduct 33 in high yield. High diastereoselectivity was again observed for the sequence 31 → 32 → 33. Intermediate 33 was transformed into 1 and 2 by standard methods.
26) The synthesis outlined in Chart 7 constitutes not only an efficient and practical route to lactacystin and omuralide, but also an excellent approach to the synthesis of numerous analogs in which the isopropyl group at C(9) in 1 and 2 is replaced by other substituents.
Synthesis and Biological Activity of Analogs of Lactacystin (1) and Omuralide (2)
The remarkable potency and specificity of lactacystin (1) and the omuralide (2) in proteasome inactivation raised the interesting questions of whether these compounds had been optimized during evolution for this purpose and whether they could be improved upon. As indicated in the preceding paragraph the synthetic approach outlined in Chart 7 provided the intermediate 32 from which a variety of C(9) substituents can be introduced to generate b-lactone analogs of type 34. By this means were synthesized not only 34, R ϭ CHϭCH 2 and R ϭ C(CH 3 )ϭCH 2 and their dihydro derivatives but also 34, R ϭ C 6 H 5 . In addition, 34, R ϭ CH 2 CHϭCH 2 and R ϭ CH 2 C(CH 3 )ϭCH 2 were prepared by the allylation of aldehyde 32 using the appropriate allyl bromide, manganese metal, and CrCl 3 as catalyst in the presence of trimethylchlorosilane, 27) and these products were converted in turn to the corresponding analogs with saturated groups at C(9). 28) The biological activity of this series of analogs, including 34, R ϭ H was assessed relative to omuralide by measurement of inactivation rate constants of purified bovine brain 20 S proteasome.
The results of the kinetic measurements are summarized in Table 1 . Clearly, the most active compound is omuralide (2) . Replacement of the C(9)-isopropyl group of 2 by hydrogen (as in 35) greatly reduces activity and substitution by phenyl (as in 36) abolishes proteasome inhibition. Similarly, activity relative to 2 is greatly diminished with C(9) substituents which are either slightly smaller than isopropyl [e.g. ethyl (37) or vinyl (38)] or larger than isopropyl [(e.g. allyl (40), n-propyl (39), methallyl (42) or isobutyl (41)]. Thus, it seems clear that the C(9)-isopropyl substituent of the natural products 1 and 2 is optimal for mammalian proteasome inhibition, implying a fairly snug fit for isopropyl in the complementary binding pocket of the proteasome. Previous biological studies established the importance of C(5)-a-hydroxyisobutyl sidechain for bioactivity. 4a) In addition, it was shown that there must be a hydroxyl group at C(6) cis to the C(4)-carboxylic group (i.e. suitably placed for b-lactone formation); 6-deoxy-and 6(R)-hydroxy analogs of lactacystin were completely inactive in proteasome inhibition. Similar studies were carried out with regard to the C(9)-hydroxyl function as summarized in Table 2 . Analogs 43 and 44 were prepared as previously described.
3) Analog 45 was prepared by catalytic hydrogenation of 46 (H 2 , Pd-C) which was synthesized from aldehyde 32 by the sequence (1) Wittig reaction with (CH 3 ) 2 CϭPPh 3 , (2) ester hydrolysis, (3) blactonization, and (4) N-deprotection, essentially using the methodology outlined in Chart 7. Comparison of the data in Table 2 reveals that the functionality and configuration at C(9) of 2 are critical to proteasome inhibition and that the omuralide structure 2 is optimal with respect to bioactivity.
We have also investigated the relationship between the nature of the substitution at C(7) in analogs of omuralide and ability to inactivate the mammalian 20 S proteasome. The analogs which were prepared and tested (47-52) are shown in Table 3 . The synthesis of these compounds was accomplished by the methodology described in Chart 1, as summarized in Chart 8.
15) The data in Table 3 indicate that whereas the replacement of the C(7)-methyl group of omuralide by the smaller hydrogen leads to much reduced activity (47), replacement of the C(7) methyl group by the larger substituents ethyl (48), n-butyl (49), or isopropyl (50) results in an approximate doubling of the proteasome inhibitory activity relative to 2. The C(7)-diastereomer of 2 (52) and the C(7)-benzyl analog (51) are somewhat less active, but still potent. Thus, in the case of the C(7)-substituent the activity of omuralide, while high, is not quite optimum.
The synthesis of an analog of omuralide having an additional methyl substituent at C(7) (53) was accomplished expeditiously as outlined in Chart 9. 29) This synthesis is both diastereocontrolled and practical. The product 53 is most interesting since it is almost as active as omuralide (K assoc. for 53, 2302 M Ϫ1 · s Ϫ1 ). The effect of changing the stereochemical orientation of the b-lactone bridge on the g-lactam nucleus has also been determined by the synthesis of b-lactones 54, the (5S,6R,9R)-diastereomer of omuralide, and 55, the (5S,6R,9S)-diastereomer of omuralide. The synthetic pathway to 54 is summarized in Chart 10. 30) Enantioselective hydrolysis of 56 gave 57 (R configuration, 83% ee) 30) which was transformed by a reaction sequence paralleling that shown in Chart 7 to diol 58 and pivolate ester 59, which could be recrystallized to enantiomeric purity.
Conversion of 59 to 60 and deacetylation (LiOH, 80°C) of 61, as shown, provided 62 which was deprotected to 54. The C(9)-diastereomer (55) of 54 was prepared similarly from the C(9)-diastereomer of 60 (a minor byproduct in the Grignard addition to form 60). The relative rates of proteasome inactivation by omuralide, 54 and 55 were found to be 3060, 121 and 0, respectively, a clear indication that the correct stereoorientation of the b-lactone bridge of omuralide is critical to bioactivity. Figure 2 summarizes all the results obtained thus far on the biological activity of lactacystin/omuralide and analogs.
